yosarian, several companies are running FGFR inhibitor trials including Novartis and AstraZeneca. The FGFR pathway has show to be active in a number of cancer types, including breast cancer, melanomas, pancreatic, prostate, ovarian, gastric and colorectal cancers.See http://www.nature.com/onc/journal/v23/n20/full/1207331a.html
In the short run, I don't see the FGFR news having much of an impact on Ariad's share price, however, I do think it serves to confirm the value of Ariad's pipeline/drug discovery capabilities in general and the value of ponatinib, in particularly. The fact that Ariad continues to own 100% of ponatinib only makes Ariad that much more attractive to any potential partner/acquirer down the road.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.